APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Myeloma Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Multiple Myeloma Drugs Industry Growth and Trends Forecast to 2032

20 December 2025101 pages

Choose your research edition.

Industry ResearchMultiple Myeloma Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Myeloma Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Multiple Myeloma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Myeloma Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Myeloma Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Multiple Myeloma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multiple Myeloma Drugs include Takeda Pharmaceutical, Teva, Johnson & Johnson, Novartis, Merck, Amgen, PharmaMar, Daiichi Sankyo and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Multiple Myeloma Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Multiple Myeloma Drugs market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Multiple Myeloma Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Multiple Myeloma Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Multiple Myeloma Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Multiple Myeloma Drugs Market by Company

Takeda Pharmaceutical

Teva

Johnson & Johnson

Novartis

Merck

Amgen

PharmaMar

Daiichi Sankyo

Celgene

AB Science

Multiple Myeloma Drugs Segment by Type

Monoclonal Antibodies

Proteasome Inhibitors

Chemotherapy

Immunomodulators

Corticosteroids

Histone Deacetylase (HDAC) Inhibitors

Others

Multiple Myeloma Drugs Segment by Application

Men

Women

Multiple Myeloma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Myeloma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Myeloma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Myeloma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Monoclonal Antibodies Table 2. Major Company of Proteasome Inhibitors Table 3. Major Company of Chemotherapy Table 4. Major Company of Immunomodulators Table 5. Major Company of Corticosteroids Table 6. Major Company of Histone Deacetylase (HDAC) Inhibitors Table 7. Major Company of Others Table 8. Global Multiple Myeloma Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 10. Global Multiple Myeloma Drugs Sales Market Share in Volume by Type (2021-2026) Table 11. Global Multiple Myeloma Drugs Sales by Type (2021-2026) & (US$ Million) Table 12. Global Multiple Myeloma Drugs Sales Market Share in Value by Type (2021-2026) Table 13. Global Multiple Myeloma Drugs Price by Type (2021-2026) & (US$/Unit) Table 14. Global Multiple Myeloma Drugs Sales by Type (2027-2032) & (W Units) Table 15. Global Multiple Myeloma Drugs Sales Market Share in Volume by Type (2027-2032) Table 16. Global Multiple Myeloma Drugs Sales by Type (2027-2032) & (US$ Million) Table 17. Global Multiple Myeloma Drugs Sales Market Share in Value by Type (2027-2032) Table 18. Global Multiple Myeloma Drugs Price by Type (2027-2032) & (US$/Unit) Table 19. North America Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 20. North America Multiple Myeloma Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 22. Europe Multiple Myeloma Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 24. Asia-Pacific Multiple Myeloma Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 26. Latin America Multiple Myeloma Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Multiple Myeloma Drugs Sales by Type (2021-2026) & (W Units) Table 28. Middle East and Africa Multiple Myeloma Drugs Sales by Type (2021-2026) & (US$ Million) Table 29. Multiple Myeloma Drugs Industry Trends Table 30. Multiple Myeloma Drugs Industry Drivers Table 31. Multiple Myeloma Drugs Industry Opportunities and Challenges Table 32. Multiple Myeloma Drugs Industry Restraints Table 33. Global Multiple Myeloma Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Multiple Myeloma Drugs Revenue Market Share by Company (2021-2026) Table 35. Global Multiple Myeloma Drugs Sales by Company (2021-2026) & (W Units) Table 36. Global Multiple Myeloma Drugs Sales Share by Company (2021-2026) Table 37. Global Multiple Myeloma Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 38. Global Multiple Myeloma Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Multiple Myeloma Drugs Major Company Production Sites and Headquarters Table 40. Global Multiple Myeloma Drugs Company, Product Type & Application Table 41. Global Multiple Myeloma Drugs Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Multiple Myeloma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Multiple Myeloma Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Multiple Myeloma Drugs Sales by Region (2021-2026) & (W Units) Table 46. Global Multiple Myeloma Drugs Sales Market Share in Volume by Region (2021-2026) Table 47. Global Multiple Myeloma Drugs Sales by Region (2021-2026) & (US$ Million) Table 48. Global Multiple Myeloma Drugs Sales Market Share in Value by Region (2021-2026) Table 49. Global Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 50. Global Multiple Myeloma Drugs Sales by Region (2027-2032) & (W Units) Table 51. Global Multiple Myeloma Drugs Sales Market Share in Volume by Region (2027-2032) Table 52. Global Multiple Myeloma Drugs Sales by Region (2027-2032) & (US$ Million) Table 53. Global Multiple Myeloma Drugs Sales Market Share in Value by Region (2027-2032) Table 54. Global Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 55. Global Multiple Myeloma Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 57. Global Multiple Myeloma Drugs Sales Market Share in Volume by Application (2021-2026) Table 58. Global Multiple Myeloma Drugs Sales by Application (2021-2026) & (US$ Million) Table 59. Global Multiple Myeloma Drugs Sales Market Share in Value by Application (2021-2026) Table 60. Global Multiple Myeloma Drugs Price by Application (2021-2026) & (US$/Unit) Table 61. Global Multiple Myeloma Drugs Sales by Application (2027-2032) & (W Units) Table 62. Global Multiple Myeloma Drugs Sales Market Share in Volume by Application (2027-2032) Table 63. Global Multiple Myeloma Drugs Sales by Application (2027-2032) & (US$ Million) Table 64. Global Multiple Myeloma Drugs Sales Market Share in Value by Application (2027-2032) Table 65. Global Multiple Myeloma Drugs Price by Application (2027-2032) & (US$/Unit) Table 66. North America Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 67. North America Multiple Myeloma Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 69. Europe Multiple Myeloma Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 71. Asia-Pacific Multiple Myeloma Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 73. Latin America Multiple Myeloma Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Multiple Myeloma Drugs Sales by Application (2021-2026) & (W Units) Table 75. Middle East and Africa Multiple Myeloma Drugs Sales by Application (2021-2026) & (US$ Million) Table 76. Takeda Pharmaceutical Company Information Table 77. Takeda Pharmaceutical Business Overview Table 78. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio Table 80. Takeda Pharmaceutical Recent Development Table 81. Teva Company Information Table 82. Teva Business Overview Table 83. Teva Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Teva Multiple Myeloma Drugs Product Portfolio Table 85. Teva Recent Development Table 86. Johnson & Johnson Company Information Table 87. Johnson & Johnson Business Overview Table 88. Johnson & Johnson Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Johnson & Johnson Multiple Myeloma Drugs Product Portfolio Table 90. Johnson & Johnson Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novartis Multiple Myeloma Drugs Product Portfolio Table 95. Novartis Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Merck Multiple Myeloma Drugs Product Portfolio Table 100. Merck Recent Development Table 101. Amgen Company Information Table 102. Amgen Business Overview Table 103. Amgen Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Amgen Multiple Myeloma Drugs Product Portfolio Table 105. Amgen Recent Development Table 106. PharmaMar Company Information Table 107. PharmaMar Business Overview Table 108. PharmaMar Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. PharmaMar Multiple Myeloma Drugs Product Portfolio Table 110. PharmaMar Recent Development Table 111. Daiichi Sankyo Company Information Table 112. Daiichi Sankyo Business Overview Table 113. Daiichi Sankyo Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio Table 115. Daiichi Sankyo Recent Development Table 116. Celgene Company Information Table 117. Celgene Business Overview Table 118. Celgene Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Celgene Multiple Myeloma Drugs Product Portfolio Table 120. Celgene Recent Development Table 121. AB Science Company Information Table 122. AB Science Business Overview Table 123. AB Science Multiple Myeloma Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. AB Science Multiple Myeloma Drugs Product Portfolio Table 125. AB Science Recent Development Table 126. North America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 127. North America Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 128. North America Multiple Myeloma Drugs Sales Market Share by Country (2021-2026) Table 129. North America Multiple Myeloma Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 130. North America Multiple Myeloma Drugs Sales Market Share Forecast by Country (2027-2032) Table 131. North America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. North America Multiple Myeloma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 133. North America Multiple Myeloma Drugs Market Share by Country (2021-2026) Table 134. North America Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. North America Multiple Myeloma Drugs Market Share Forecast by Country (2027-2032) Table 136. Europe Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 137. Europe Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 138. Europe Multiple Myeloma Drugs Sales Market Share by Country (2021-2026) Table 139. Europe Multiple Myeloma Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 140. Europe Multiple Myeloma Drugs Sales Market Share Forecast by Country (2027-2032) Table 141. Europe Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Europe Multiple Myeloma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 143. Europe Multiple Myeloma Drugs Market Share by Country (2021-2026) Table 144. Europe Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Europe Multiple Myeloma Drugs Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 148. Asia-Pacific Multiple Myeloma Drugs Sales Market Share by Country (2021-2026) Table 149. Asia-Pacific Multiple Myeloma Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 150. Asia-Pacific Multiple Myeloma Drugs Sales Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Multiple Myeloma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 153. Asia-Pacific Multiple Myeloma Drugs Market Share by Country (2021-2026) Table 154. Asia-Pacific Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Asia-Pacific Multiple Myeloma Drugs Market Share Forecast by Country (2027-2032) Table 156. Latin America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 157. Latin America Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 158. Latin America Multiple Myeloma Drugs Sales Market Share by Country (2021-2026) Table 159. Latin America Multiple Myeloma Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 160. Latin America Multiple Myeloma Drugs Sales Market Share Forecast by Country (2027-2032) Table 161. Latin America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Latin America Multiple Myeloma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 163. Latin America Multiple Myeloma Drugs Market Share by Country (2021-2026) Table 164. Latin America Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Latin America Multiple Myeloma Drugs Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 168. Middle East and Africa Multiple Myeloma Drugs Sales Market Share by Country (2021-2026) Table 169. Middle East and Africa Multiple Myeloma Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 170. Middle East and Africa Multiple Myeloma Drugs Sales Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Multiple Myeloma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 173. Middle East and Africa Multiple Myeloma Drugs Market Share by Country (2021-2026) Table 174. Middle East and Africa Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Middle East and Africa Multiple Myeloma Drugs Market Share Forecast by Country (2027-2032) Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Multiple Myeloma Drugs Distributors List Table 179. Multiple Myeloma Drugs Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Multiple Myeloma Drugs Image Figure 2. Global Multiple Myeloma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Myeloma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Myeloma Drugs Sales (2021-2032) & (W Units) Figure 5. Monoclonal Antibodies Image Figure 6. Global Monoclonal Antibodies Sales YoY Growth (2021-2032) & (W Units) Figure 7. Proteasome Inhibitors Image Figure 8. Global Proteasome Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 9. Chemotherapy Image Figure 10. Global Chemotherapy Sales YoY Growth (2021-2032) & (W Units) Figure 11. Immunomodulators Image Figure 12. Global Immunomodulators Sales YoY Growth (2021-2032) & (W Units) Figure 13. Corticosteroids Image Figure 14. Global Corticosteroids Sales YoY Growth (2021-2032) & (W Units) Figure 15. Histone Deacetylase (HDAC) Inhibitors Image Figure 16. Global Histone Deacetylase (HDAC) Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 19. Global Multiple Myeloma Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Multiple Myeloma Drugs Market Share by Type 2025 VS 2032 Figure 21. North America Multiple Myeloma Drugs Sales Market Share in Volume by Type in 2025 Figure 22. North America Multiple Myeloma Drugs Sales Market Share in Value by Type in 2025 Figure 23. Europe Multiple Myeloma Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Europe Multiple Myeloma Drugs Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Multiple Myeloma Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Multiple Myeloma Drugs Sales Market Share in Value by Type in 2025 Figure 27. Latin America Multiple Myeloma Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Multiple Myeloma Drugs Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Multiple Myeloma Drugs Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Multiple Myeloma Drugs Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Multiple Myeloma Drugs Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Men Image Figure 34. Global Men Sales YoY Growth (2021-2032) & (W Units) Figure 35. Women Image Figure 36. Global Women Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Multiple Myeloma Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Multiple Myeloma Drugs Market Share by Application 2025 VS 2032 Figure 39. North America Multiple Myeloma Drugs Sales Market Share in Volume by Application in 2025 Figure 40. North America Multiple Myeloma Drugs Sales Market Share in Value by Application in 2025 Figure 41. Europe Multiple Myeloma Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Europe Multiple Myeloma Drugs Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Multiple Myeloma Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Multiple Myeloma Drugs Sales Market Share in Value by Application in 2025 Figure 45. Latin America Multiple Myeloma Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Multiple Myeloma Drugs Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Multiple Myeloma Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Multiple Myeloma Drugs Sales Market Share in Value by Application in 2025 Figure 49. North America Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Multiple Myeloma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Multiple Myeloma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Multiple Myeloma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Multiple Myeloma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Multiple Myeloma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Multiple Myeloma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Multiple Myeloma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Multiple Myeloma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Multiple Myeloma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Multiple Myeloma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Multiple Myeloma Drugs Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Multiple Myeloma Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Proteasome Inhibitors
  • Chemotherapy
  • Immunomodulators
  • Corticosteroids
  • Histone Deacetylase (HDAC) Inhibitors
  • Others
Applications
  • Men
  • Women
Companies covered
  • Takeda Pharmaceutical
  • Teva
  • Johnson & Johnson
  • Novartis
  • Merck
  • Amgen
  • PharmaMar
  • Daiichi Sankyo
  • Celgene
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Multiple Myeloma Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Multiple Myeloma Drugs Market by Type
  6. 1.3.1 Monoclonal Antibodies
  7. 1.3.2 Proteasome Inhibitors
  8. 1.3.3 Chemotherapy
  9. 1.3.4 Immunomodulators
  10. 1.3.5 Corticosteroids
  11. 1.3.6 Histone Deacetylase (HDAC) Inhibitors
  12. 1.3.7 Others
  13. 1.4 Global Multiple Myeloma Drugs Market Size by Type
  14. 1.4.1 Global Multiple Myeloma Drugs Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Multiple Myeloma Drugs Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Multiple Myeloma Drugs Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Multiple Myeloma Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Multiple Myeloma Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Multiple Myeloma Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Multiple Myeloma Drugs Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Multiple Myeloma Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Multiple Myeloma Drugs Industry Trends
  2. 2.2 Multiple Myeloma Drugs Industry Drivers
  3. 2.3 Multiple Myeloma Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Myeloma Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Multiple Myeloma Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Multiple Myeloma Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Multiple Myeloma Drugs Price (2021-2026)
  4. 3.4 Global Multiple Myeloma Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multiple Myeloma Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Multiple Myeloma Drugs Company, Product Type & Application
  7. 3.7 Global Multiple Myeloma Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multiple Myeloma Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multiple Myeloma Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multiple Myeloma Drugs Tier 1, Tier 2, and Tier 3
4 Multiple Myeloma Drugs Regional Status and Outlook
  1. 4.1 Global Multiple Myeloma Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Multiple Myeloma Drugs Historic Market Size by Region
  3. 4.2.1 Global Multiple Myeloma Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Multiple Myeloma Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Multiple Myeloma Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Multiple Myeloma Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Multiple Myeloma Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Multiple Myeloma Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Multiple Myeloma Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Multiple Myeloma Drugs by Application
  1. 5.1 Multiple Myeloma Drugs Market by Application
  2. 5.1.1 Men
  3. 5.1.2 Women
  4. 5.2 Global Multiple Myeloma Drugs Market Size by Application
  5. 5.2.1 Global Multiple Myeloma Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Multiple Myeloma Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Multiple Myeloma Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Multiple Myeloma Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Multiple Myeloma Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Multiple Myeloma Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Multiple Myeloma Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Multiple Myeloma Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical
  2. 6.1.1 Takeda Pharmaceutical Company Information
  3. 6.1.2 Takeda Pharmaceutical Business Overview
  4. 6.1.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Multiple Myeloma Drugs Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Johnson & Johnson
  14. 6.3.1 Johnson & Johnson Company Information
  15. 6.3.2 Johnson & Johnson Business Overview
  16. 6.3.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
  18. 6.3.5 Johnson & Johnson Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Multiple Myeloma Drugs Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Multiple Myeloma Drugs Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Amgen
  32. 6.6.1 Amgen Company Information
  33. 6.6.2 Amgen Business Overview
  34. 6.6.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Amgen Multiple Myeloma Drugs Product Portfolio
  36. 6.6.5 Amgen Recent Developments
  37. 6.7 PharmaMar
  38. 6.7.1 PharmaMar Company Information
  39. 6.7.2 PharmaMar Business Overview
  40. 6.7.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
  42. 6.7.5 PharmaMar Recent Developments
  43. 6.8 Daiichi Sankyo
  44. 6.8.1 Daiichi Sankyo Company Information
  45. 6.8.2 Daiichi Sankyo Business Overview
  46. 6.8.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
  48. 6.8.5 Daiichi Sankyo Recent Developments
  49. 6.9 Celgene
  50. 6.9.1 Celgene Company Information
  51. 6.9.2 Celgene Business Overview
  52. 6.9.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Celgene Multiple Myeloma Drugs Product Portfolio
  54. 6.9.5 Celgene Recent Developments
  55. 6.10 AB Science
  56. 6.10.1 AB Science Company Information
  57. 6.10.2 AB Science Business Overview
  58. 6.10.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AB Science Multiple Myeloma Drugs Product Portfolio
  60. 6.10.5 AB Science Recent Developments
7 North America by Country
  1. 7.1 North America Multiple Myeloma Drugs Sales by Country
  2. 7.1.1 North America Multiple Myeloma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Multiple Myeloma Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Multiple Myeloma Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Multiple Myeloma Drugs Market Size by Country
  6. 7.2.1 North America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Multiple Myeloma Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Multiple Myeloma Drugs Sales by Country
  2. 8.1.1 Europe Multiple Myeloma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Multiple Myeloma Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Multiple Myeloma Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Multiple Myeloma Drugs Market Size by Country
  6. 8.2.1 Europe Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Multiple Myeloma Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Multiple Myeloma Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Multiple Myeloma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Multiple Myeloma Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Multiple Myeloma Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Multiple Myeloma Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Multiple Myeloma Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Multiple Myeloma Drugs Sales by Country
  2. 10.1.1 South America Multiple Myeloma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Multiple Myeloma Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Multiple Myeloma Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Multiple Myeloma Drugs Market Size by Country
  6. 10.2.1 South America Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Multiple Myeloma Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Multiple Myeloma Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Multiple Myeloma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Multiple Myeloma Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Multiple Myeloma Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Multiple Myeloma Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Multiple Myeloma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Multiple Myeloma Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Multiple Myeloma Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Multiple Myeloma Drugs Value Chain Analysis
  2. 12.1.1 Multiple Myeloma Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Multiple Myeloma Drugs Production Mode & Process
  7. 12.2 Multiple Myeloma Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Multiple Myeloma Drugs Distributors
  10. 12.2.3 Multiple Myeloma Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst